Sana Biotechnology (SANA) Short term Debt (2021 - 2026)

Sana Biotechnology's Short term Debt history runs 5 years deep, the most recent figure standing at $53.6 million for Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $53.6 million; the TTM figure through Mar 2026 stood at $53.6 million (changed N/A YoY), while the FY2025 annual figure was $40.2 million, changed N/A from the prior year.
• Short term Debt came in at $53.6 million for Q1 2026 at Sana Biotechnology, up from $40.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $59.4 million in Q3 2022 to a low of $40.2 million in Q4 2025.
• A 4-year average of $53.3 million and a median of $54.5 million in 2022 frame the typical range for Short term Debt.
• On a YoY basis, Short term Debt climbed as much as 36.75% in 2022 and fell as far as 7.71% in 2022.
• Sana Biotechnology's Short term Debt stood at $55.3 million in 2022, then increased by 5.55% to $58.4 million in 2023, then plunged by 31.18% to $40.2 million in 2025, then surged by 33.22% to $53.6 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $53.6 million, $40.2 million, and $58.4 million for Q1 2026, Q4 2025, and Q2 2023 respectively.

Peer Comparison